Search research articles
Contact Us
Filters
Showing results (31-40 of 225) with videos related to
Page
of 23
Sort By:
Clinical Lung Cancer
|
June 8, 2020
Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
Melina E Marmarelis, Corey J Langer
Seminars in Oncology
|
February 26, 2004
The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
Fred R Hirsch, Corey J Langer
Cancer Investigation
|
April 9, 2005
Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report
Robert A Somer, Corey J Langer
Seminars in Oncology
|
February 7, 2006
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors
Corey J Langer, Ronald B Natale
Clinical Advances in Hematology & Oncology : H&O
|
May 24, 2007
The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS 2 patients
John G Devlin, Corey J Langer
Seminars in Oncology
|
March 15, 2002
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers
Roy S Herbst, Corey J Langer
Expert Review of Anticancer Therapy
|
March 7, 2007
Combined modality treatment of laryngeal squamous cell carcinoma
John G Devlin, Corey J Langer
Clinical Lung Cancer
|
June 15, 2007
Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature
John G Devlin, Corey J Langer
Seminars in Radiation Oncology
|
June 13, 2012
Retreatment of recurrent head and neck cancer in a previously irradiated field
Stuart J Wong, Jean Bourhis, Corey J Langer
Seminars in Radiation Oncology
|
February 21, 2021
Systemic Therapy for Mutation-Driven NSCLC
Lova Sun, Melina E Marmarelis, Corey J Langer
Page
of 23
Search research articles
Search
Showing results (31-40 of 225) with videos related to
Sort By:
Page
of 23
Clinical Lung Cancer
|
June 8, 2020
Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
Melina E Marmarelis, Corey J Langer
Seminars in Oncology
|
February 26, 2004
The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
Fred R Hirsch, Corey J Langer
Cancer Investigation
|
April 9, 2005
Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report
Robert A Somer, Corey J Langer
Seminars in Oncology
|
February 7, 2006
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors
Corey J Langer, Ronald B Natale
Clinical Advances in Hematology & Oncology : H&O
|
May 24, 2007
The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS 2 patients
John G Devlin, Corey J Langer
Seminars in Oncology
|
March 15, 2002
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers
Roy S Herbst, Corey J Langer
Expert Review of Anticancer Therapy
|
March 7, 2007
Combined modality treatment of laryngeal squamous cell carcinoma
John G Devlin, Corey J Langer
Clinical Lung Cancer
|
June 15, 2007
Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature
John G Devlin, Corey J Langer
Seminars in Radiation Oncology
|
June 13, 2012
Retreatment of recurrent head and neck cancer in a previously irradiated field
Stuart J Wong, Jean Bourhis, Corey J Langer
Seminars in Radiation Oncology
|
February 21, 2021
Systemic Therapy for Mutation-Driven NSCLC
Lova Sun, Melina E Marmarelis, Corey J Langer
Page
of 23